Maryland Heights, MO, March 08, 2017 --(PR.com
)-- The global hypertrophic cardiomyopathy therapeutics market growing at a rate of 1.8% CAGR, is estimated to reach USD 1.2 Billion by 2020 due to higher incidence chronic cardiovascular diseases worldwide.
Browse Hypertrophic Cardiomyopathy Therapeutics Market by Drug Classes (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, and Calcium Channel Blockers) and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs 2016-2020 at https://www.ihealthcareanalyst.com/report/hypertrophic-cardiomyopathy-therapeutics-market/
Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease with a diverse clinical presentation and course. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. Despite this thickening, the ventricle size often remains normal. However, the thickening may block blood flow out of the ventricle and the condition is called obstructive hypertrophic cardiomyopathy. Sudden death is most common in young patients, and death from heart failure or stroke occurs more frequently in middle and old age. HCM is also a common inherited heart disease with serious adverse outcomes, including heart failure, arrhythmias, and sudden cardiac death. Medications include beta blockers, calcium channel blockers, antiarrhythmic drugs, and anti-coagulating agents, and rarely, diltiazem, amiodarone, and disopyramide.
The global hypertrophic cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiarrhythmic agents, anticoagulants, beta adrenergic blocking agents, and calcium channel blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2016 to 2020). The global hypertrophic cardiomyopathy therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hypertrophic cardiomyopathy therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global hypertrophic cardiomyopathy therapeutics market and included in this report are Pfizer, Inc., Merck & Co., Teva Pharmaceuticals Ltd., Mylan N.V., Novartis AG, and Sanofi S.A.
To request Table of Contents and Sample Pages of this report visit:
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043